1. Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial
- Author
-
Andrea Pace, Giuseppe Lombardi, Veronica Villani, Dario Benincasa, Claudia Abbruzzese, Ilaria Cestonaro, Martina Corrà, Marta Padovan, Giulia Cerretti, Mario Caccese, Antonio Silvani, Paola Gaviani, Diana Giannarelli, Gennaro Ciliberto, and Marco G. Paggi
- Subjects
glioblastoma ,drug repurposing ,chlorpromazine ,adjuvant treatment ,MGMT ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
IntroductionDrug repurposing is a promising strategy to develop new treatments for glioblastoma. In this phase II clinical trial, we evaluated the addition of chlorpromazine to temozolomide in the adjuvant phase of the standard first-line therapeutic protocol in patients with unmethylated MGMT gene promoter.MethodsThis was a multicenter phase II single-arm clinical trial. The experimental procedure involved the combination of CPZ with standard treatment with TMZ in the adjuvant phase of the Stupp protocol in newly-diagnosed GBM patients carrying an unmethylated MGMT gene promoter. Progression-free survival was the primary endpoint. Secondary endpoints were overall survival and toxicity.ResultsForty-one patients were evaluated. Twenty patients (48.7%) completed 6 cycles of treatment with TMZ+CPZ. At 6 months, 27 patients (65.8%) were without progression, achieving the primary endpoint. Median PFS was 8.0 months (95% CI: 7.0-9.0). Median OS was 15.0 months (95% CI: 13.1-16.9). Adverse events led to reduction or interruption of CPZ dosage in 4 patients (9.7%).DiscussionThe addition of CPZ to standard TMZ in the first-line treatment of GBM patients with unmethylated MGMT gene promoter was safe and led to a longer PFS than expected in this population of patients. These findings provide proof-of-concept for the potential of adding CPZ to standard TMZ treatment in GBM patients with unmethylated MGMT gene promoter.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04224441, identifier NCT04224441.
- Published
- 2023
- Full Text
- View/download PDF